Historically, the use of viruses in anticancer therapy has been judged to be a 'fringe' and 'far-fetched' approach with little credibility outside of a few practitioners of 'virotherapy' . In the age of precision medicine and targeted therapies, treatments involving relatively untargeted pathogens have not context, the pleiotropic mechanisms of tumour cell-killing engaged by virotherapy are postulated to be advantageous in addressing intratumoural heterogeneity 2 . In fact, the past 3 years have seen a sudden proliferation of reports of different oncolytic virotherapies being published in very high-impact journals 3, 4 . These studies have revealed that virotherapy can be very effective in turning the tumour microenvironment from an immunosuppressed (cold) to an inflamed (hot) state (Fig. 1) . Thus, virotherapy has progressed from being a 'benchwarming' player to the new exciting 'quarterback' orchestrating the offensive against cancer.
The latest addition to the roster of oncolytic virotherapies is an engineered poliovirus (PVSRIPO) that has recently been tested in a phase I clinical trial involving 61 patients with biopsy-proven recurrent glioblastoma 5 . The patients did not undergo cytoreductive surgery; instead the tumours were directly infused with PVSRIPO by convection-enhanced delivery. Outcomes were compared with those of a matched historical control group from the same institution. No adverse events directly attributed to neurovirulence were reported; however, 69% of patients had transient neurological complications owing to reactive inflammation and brain oedema following virus administration, although the symptoms been fashionable in oncology. Over time, however, the tremendous intratumoural genetic and signalling heterogeneity of solid neoplasms, such as glioblastoma, became recognized as an almost insurmountable limitation to therapies targeting one or a few mutations or aberrant pathways 1 . In this
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were successfully treated with steroids or bevacizumab. The median survival of 12.5 months in PVSRIPO-treated patients was not markedly different from that of the historical control group (11.3 months). Nevertheless, the study was notable for a 'tail' of the survival curve plateauing at 21% after 24 months with PVSRIPO, whereas survival in the control group continued to decline from 14% at this time point to <2% beyond 48 months. More significantly, 8 patients in the PVSRIPO group reached the 2-year landmark, 5 of whom also reached the 3-year landmark, and 4 survivors remained alive at 41, 57, 69, and 70 months at the data analysis cut-off date (March 2018) 5 . These long-term durable responses explain the excitement generated by the trial.
PVSRIPO possesses several biological features that might explain its anticancer properties 6 . First, the virus rapidly hijacks the cell's synthetic machinery upon infe ction and is, therefore, very efficient at killing tumour cells. Second, a transgenic molecular switch ensures selective replication in cancer cells and not nonmalignant cells of the central nervous system. Third, entry of the virus into cells is dependent on CD155, a membrane protein overexpressed by tumour cells. Fourth, upon infection, the virus triggers a potent innate immune response mediated by type 1 interferons (IFNs). This response is innocuous to the PVSRIPO virus itself, which produces a protease that disrupts host cell protein synthesis while selective viral translation is maintained, thereby enabling continued viral replication and spread; however, IFN response does result in a localized inflammatory reaction and the recruitment of activated neutrophils and macrophages to the tumour microenvironment. Finally, PVSRIPO infects antigen-presenting cells but does not lyse them, inducing a protracted inflammatory milieu and activation of adaptive immunity, including cytotoxic T lymphocyte responses against tumour antigens.
At first glance, the potential survival benefit associated with PVSRIPO seems surprising and very exciting, perhaps exceeding the results obtained with other experimental agents in similar clinical settings. However, published results from trials of other virotherapies also demonstrate that a small subset of patients have durable clinical responses. For instance, the investigators of a very similar trial 3 , in which patients with recurrent glioblastoma underwent biopsy sampling and then intratumoural injection of a tumour cell-selective adenovirus establish whether PVSRIPO is a 'franchise player' in anticancer therapy -or just another 'journeyman'. Yet, a single-shot therapy that can potentially actuate multiple anticancer mechanisms (direct cytotoxicity, induction of cytokines and danger signals, activation of innate immunity, and activation of effector T cell immunity; Fig. 1 ) does provide a possible solution to the problem of intra tumoural heterogeneity; therein lies the most exciting justification for virotherapy against cancer.
